Gap 27

Gap 27 is a synthetic peptide compound specifically designed to modulate gap junctional intercellular communication by targeting connexin proteins, particularly connexin43. As a connexin mimetic peptide, Gap 27 plays a critical role in the study of cell-to-cell communication, tissue homeostasis, and cellular signaling pathways. Its unique sequence enables selective interference with gap junction channels, making it an essential tool for researchers investigating the physiological and pathological roles of connexins in various biological systems. The compound's ability to transiently inhibit gap junctional conductance without broadly disrupting cellular viability or function underpins its value in both basic and applied research settings.

Connexin function studies: Gap 27 is widely employed in the elucidation of connexin-mediated signaling mechanisms. By mimicking a specific extracellular loop sequence of connexin43, the peptide competitively inhibits gap junction channel formation or function, allowing researchers to dissect the contribution of connexin43-mediated intercellular communication in diverse cellular contexts. This selective inhibition is particularly valuable for distinguishing the roles of specific connexin isoforms in processes such as cardiac conduction, wound healing, and neural signaling.

Cellular communication assays: In vitro and ex vivo models frequently utilize Gap 27 to probe the dynamics of gap junctional intercellular communication (GJIC). The peptide serves as a reversible modulator, enabling precise temporal control over gap junction activity during experimental manipulation. Researchers leverage this property to investigate the impact of altered GJIC on cell proliferation, migration, differentiation, and response to external stimuli, thereby advancing the understanding of multicellular coordination in both normal and stressed tissues.

Tissue injury and repair models: Gap 27 is instrumental in studies exploring the role of gap junctions in tissue damage and regeneration. By transiently blocking connexin43-mediated communication, the peptide allows for the assessment of how altered gap junctional signaling influences cellular responses during injury, inflammation, and the early phases of tissue repair. Such investigations provide mechanistic insights into the regulation of cellular behavior in response to environmental challenges, supporting the development of strategies for tissue engineering and regenerative medicine research.

Electrophysiological investigations: The selective action of Gap 27 on gap junction channels makes it a valuable reagent in electrophysiological studies. Researchers use the peptide to modulate intercellular electrical coupling in cardiac, neural, and smooth muscle preparations, facilitating the analysis of the direct contributions of gap junctions to synchronized electrical activity. This application is central to advancing knowledge of arrhythmogenic mechanisms, synaptic integration, and coordinated contraction in excitable tissues.

Peptide-based screening and drug discovery: Gap 27 serves as a reference compound in the screening of novel modulators of gap junction function. Its well-characterized mechanism of action and specificity for connexin43 make it a benchmark for evaluating the efficacy and selectivity of new peptide analogs, small molecules, or biologics targeting gap junctions. This role is particularly relevant in early-stage drug discovery and the development of research tools aimed at modulating intercellular communication pathways for experimental purposes.

1. SERS spectrum of the peptide thymosin‐β4 obtained with Ag nanorod substrate

2. An Open-label, Single-center, Safety and Efficacy Study of Eyelash Polygrowth Factor Serum

3. Immune-awakening Saccharomyces-inspired nanocarrier for oral target delivery to lymph and tumors

4. Genetic, cellular, and structural characterization of the membrane potential-dependent cell-penetrating peptide translocation pore

5. The effect of sex on immune responses to a homocitrullinated peptide in the DR4-transgenic mouse model of Rheumatoid Arthritis